INS and neoplasm: Emerging evidence suggests that SGLT2 inhibitors may exert antineoplastic properties through multiple mechanisms, including metabolic reprogramming, the reduction of insulin and glucose availability in the tumor microenvironment, and attenuation of inflammation.